Searched for
BIOCON SERUM
Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...- 'Biocon looking at options to cut debt taken for Viatris' business buy'"We are looking at a number of options to reduce that... I can say that you'll see the debt level coming down in the coming quarters," he s...
- Trying to raise an additional $300 million to further reduce debt: Kiran Mazumdar Shaw, BioconWe are progressing well with various interested investors and we will obviously share it with you as and when we conclude these investment ...
- Serum Institute to double investment in Biocon Biologics to $300 millionSerum Institute of Life Sciences (SILS) has converted a $150 million loan into equity, increasing its investment in Biocon Biologics. This ...
- Serum Life Sciences to double investments in Biocon Biologics to $300 million under new arrangementUnder the fresh terms of their strategic alliance, Serum Life Sciences will make an additional equity investment of $150 million through th...
- India's Serum to double investment in Biocon's unit to $300 mlnSerum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker. Under new terms of the alliance,...
- Buy Biocon, target price Rs 375: JM FinancialBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 28934.46 Crore) operating in Pharmaceuticals secto...
- Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- CCI clears Serum Institute Life Sciences-Biocon Biologics dealOnce the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...
- Biocon Q4 Results: Profit declines 4% to Rs 283 crConsolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Serum Institute to invest $68 million in UK vaccine maker Oxford BiomedicaSerum Life Sciences Ltd, a unit of India-based SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal. Oxford Biomedica, sp...
- Can Serum deal provide a booster dose to Biocon's target price?The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...
- Biocon Biologics, Serum Institute Life Sciences to expand tie-up for R&D, new vaccinesOn Thursday, Biocon had said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about Rs3...
- Kiran Mazumdar-Shaw & Adar Poonawalla spell out the road map for Biocon-Serum alliance"The Biocon-Serum alliance will initially focus on Covid vaccines, because that is the need of the hour. At a later stage, we will see what...
- Biocon unit plans 15% stake sale to Serum Institute for access to vaccinesThe deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the...
- Biocon Biologics to offer 15% stake to Serum Institute Life SciencesUnder the alliance, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of th...
Load More
